
Cell Line Data Sheet for CHLA-42

Disease: Neuroblastoma
Phase of Therapy: Diagnosis
Treatment: None
Disease Stage: 4
Gender: Female
Age at diagnosis: 13 months
Race: N/A
Age at sample collection: N/A
Source of Culture: Bone Marrow
Primary Tumor Site: N/A
Date Established: September 1989

MYCN Patient: Non-amplified
MYCN Cell line: N/A
THmRNA: Expressed
p53 functionality: N/A
Telomere mechanism: N/A
ALK: R1275Q
RNAseq: N/A
WES: N/A

Growth Conditions: Please see Protocols section at <https://www.cccells.org/protocols.php>
 5% CO₂, 20% O₂, 37.0°C

Media Formulation: Please see Protocols section at <https://www.cccells.org/protocols.php>
 Cells are grown in a base medium of Iscove's Modified Dulbecco's Medium plus the following supplements (to a final concentration): 20% Fetal Bovine Serum, 4mM L-Glutamine, 1X ITS (5 µg/mL insulin, 5 µg/mL transferrin, 5 ng/mL selenous acid)

Doubling Time: N/A
Growth Properties: Adherent, grows mostly in clumps

STR Profile: May be obtained at <https://strdb.cccells.org/>
Notes: None

All COG Repository cell lines are antibiotic-free, mycoplasma-free, and cryopreserved in 50% FBS / 7.5% DMSO. Each vial label contains the cell line name, passage number, total viable cell count (usually 5-10e6), the overall cell viability, and date frozen. All cell lines are validated with original patient sample by STR analysis.



Cell Line Data Sheet for CHLA-42

Cell Line Name: CHLA-42

References:


1. Keshelava N, Seeger RC, Groshen S, Reynolds CP: Drug resistance patterns of human neuroblastoma cell lines derived from patients at different phases of therapy. *Cancer Res.* 58:5396-5405, 1998
PubMed ID: [9850071](https://pubmed.ncbi.nlm.nih.gov/9850071/)
<https://cancerres.aacrjournals.org/content/58/23/5396.long>
2. Keshelava N, Groshen S, Reynolds CP. Cross-resistance of topoisomerase I and II inhibitors in neuroblastoma cell lines. *Cancer Chemoth Pharm.* 45: 1-8, 2000. PubMed ID: [10647494](https://pubmed.ncbi.nlm.nih.gov/10647494/)
<https://link.springer.com/article/10.1007%2FPL00006736>
3. Thompson PM, Maris JM, Hogarty MD, Seeger RC, Reynolds CP, Brodeur GM, White PS. Homozygous deletion of CDKN2A (p16INK4a/p14ARF) but not within 1p36 or at Other Tumor Suppressor Loci in Neuroblastoma. *Cancer Res.* 61, 679-686, 2001. PubMed ID: [11212268](https://pubmed.ncbi.nlm.nih.gov/11212268/)
<https://cancerres.aacrjournals.org/content/61/2/679.long>
4. Keshelava N, Davicioni E, Wan Z, Ji L, Sposto R, Triche TJ, Reynolds CP. Histone Deacetylase 1 Gene Expression and Sensitization of Multidrug-Resistant Neuroblastoma Cell Lines to Cytotoxic Agents by Depsipeptide. *J Natl Cancer I.* 99: 1107-19, 2007.
PubMed ID: [17623797](https://pubmed.ncbi.nlm.nih.gov/17623797/)
<https://academic.oup.com/jnci/article/99/14/1107/938992>
5. Harned TM, Kalous O, Neuwelt A, Loera J, Ji L, Iovine P, Sposto R, Neuwelt EA, Reynolds CP: Sodium Thiosulfate (STS) administered six hours after cisplatin does not compromise anti-neuroblastoma activity. *Clin Cancer Res.* 14:533-540, 2008. PubMed ID: [18223229](https://pubmed.ncbi.nlm.nih.gov/18223229/)
<https://clincancerres.aacrjournals.org/content/14/2/533.long>
6. Kang MH, Smith MA, Morton CL, Keshelava N, Houghton PJ, Reynolds CP. National Cancer Institute Pediatric Preclinical Testing Program: Model Description for In Vitro Cytotoxicity Testing. *Pediatr Blood Cancer.* 56: 239-249, 2011. PubMed ID: [20922763](https://pubmed.ncbi.nlm.nih.gov/20922763/)
<https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3005554/>

(www.PPTPinvitro.org)


Cell Line Data Sheet for CHLA-42

Cell Line Name: CHLA-42


(10x magnification)



(10x magnification)



(20x magnification)



(20x magnification)

